Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 29 May 2008

European Journal of Endocrinology 2008;159:121.

DOI: 10.1530/EJE-08-0097
Copyright © 2008 by European Society of Endocrinology
This Article
Right arrow Accepted manuscript (PDF)
Right arrow All Versions of this Article:
EJE-08-0097v1
159/2/121    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vrbikova, J.
Right arrow Articles by Pacini, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vrbikova, J.
Right arrow Articles by Pacini, G.

RESEARCH

Incretin levels in polycystic ovary syndrome

Jana Vrbikova, Martin Hill, Bela Bendlova, Tereza Grimmichova, Katerina Dvorakova, Karel Vondra and Giovanni Pacini

J Vrbikova, Clinical Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic
M Hill, Department of steroid hormones, Institute of Endocrinology, Prague, Czech Republic
B Bendlova, Molecular Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic
T Grimmichova, Department of Functional Diagnostics, Institute of Endocrinology, Prague 1, United Kingdom
K Dvorakova, Clinical Endocrinology, Institute of Endocrinology, Praha 1, 116 94, Czech Republic
K Vondra, Department of Functional Diagnostics, Institute of Endocrinology, Prague 1, United Kingdom
G Pacini, Metabolic Unit, Institute of Biomedical Engineering, National Research Council,, Padova, Italy

Correspondence: Katerina Dvorakova, Email: kdvorakova{at}endo.cz

Abstract

Objective: Polycystic ovary syndrome (PCOS) is linked to a high risk of type 2 diabetes mellitus (T2DM). Disturbances in the secretion of glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP 1) have been observed in states with impaired glucose regulation. Design: Case control.Methods: PCOS (n=21, 25.8±4.1 years, BMI 21.6±1.7 kg/m2) and control healthy women (CT, n=13, 28.5±7.2 years, BMI 20.3±2.5 kg/m 2) underwent OGTT with blood sampling for glucose, insulin, C peptide, total GIP and active GLP 1. Insulin sensitivity was determined both at fasting and during the test.Statistics: Repeated measures ANOVA.Results: Glucose levels and insulin sensitivity did not differ between PCOS and CT. PCOS had significantly higher levels of C peptide (p≤0.05), and tended to have higher insulin levels. The levels of total GIP were significantly higher in PCOS than in CT (p≤0.001). Active GLP 1 levels exhibited a significantly different time dependent pattern in PCOS (p≤0.008 for PCOS vs. time interaction). GLP 1 concentrations were similar in PCOS and CT in the early phase of OGTT and then reached significantly lower levels in PCOS than in CT at 180 mins (p≤0.05).

Conclusions: Increased total GIP and lower late phase active GLP 1 concentrations during OGTT characterize PCOS women with higher C peptide secretion in comparison to healthy controls, and may be the early markers of a pre diabetic state.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 European Society of Endocrinology.